A trial in the UK will see a norovirus given to patients with the Health Secretary hoping it will cut the “burden on the NHS”.

A randomised clinical trial of an mRNA vaccine against norovirus will be launched in the UK within the next two weeks, it has ...

COVID-19 2024–2025 vaccines are recommended for everyone aged 6 months and older, with vaccines targeting the JN.1 and KP.2 strains of SARS-CoV-2.

In this piece, we will look at where Moderna, Inc. (NASDAQ:MRNA) sits on the fund managers’ radar. The surge in interest ...

We recently published a list of 10 Best Depressed Stocks To Buy Heading into 2025. In this article, we are going to take a ...

There’s change at the top of Ogilvy Health. Kim Johnson is leaving to pursue new opportunities after three years as CEO, ...

For anyone without insurance, you can find a free flu shot provider under the state Department of Health Services Vaccines ...

A world-first vaccine for the vomiting bug norovirus is being trialled in the UK, with the hope it could cut the "burden" on ...

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...